Comment on

• Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

  Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, Gordon S, Ahmed R, Nichols A, Rothe M, Rosmarin D. Abdat R, et al. J Am Acad Dermatol. 2020 Jul;83(1):46-52. doi: 10.1016/j.jaad.2020.01.089. Epub 2020 Mar 13. J Am Acad Dermatol. 2020. PMID: 32179082
• Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients.

  Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, Pontes DS, Silverberg JI, Choi J, Pro B, Pincus LB, Guitart J, Zhou XA. Espinosa ML, et al. J Am Acad Dermatol. 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27. J Am Acad Dermatol. 2020. PMID: 32229275 Free PMC article. No abstract available.
• Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.

  Chiricozzi A, Maurelli M, Gori N, Argenziano G, De Simone C, Calabrese G, Girolomoni G, Peris K. Chiricozzi A, et al. J Am Acad Dermatol. 2020 Jul;83(1):39-45. doi: 10.1016/j.jaad.2020.03.049. Epub 2020 Mar 27. J Am Acad Dermatol. 2020. PMID: 32229281